Vaxcyte ( (PCVX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vaxcyte’s stock is on the rise due to a 15-year agreement with Patheon and progress in its VAX-31 infant Phase 2 study. These developments have led to optimistic price targets, bolstered by strategic manufacturing expansions and advancements in vaccine development. Despite a mixed initiation by Goldman Sachs, the overall analyst consensus remains a Strong Buy.
More about Vaxcyte
YTD Price Performance: -51.82%
Average Trading Volume: 1,576,180
Technical Sentiment Signal: Sell
Current Market Cap: $4.94B
For further insights into PCVX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.